Seattle, WA
Alpine Immune Sciences, Inc. (AIS) focuses on developing novel protein-based cancer immunotherapies using its proprietary variant ig domain (vIgD) platform technology. The Company develops TIP technology, based on the vIgD platform, to enhance engineered cellular therapies. AIS offers a platform to interact with multiple targets, including many present in the immune synapse.
alpineimmunesciences.comThese are collections Alpine Immune Sciences is a part of. Click on the collection name to view similar companies.
Post Ipo Equity
$150,000,000
Post Ipo Equity
$100,000,000
Post Ipo Equity
$91,000,000
Post Ipo Equity
$60,000,000
Post Ipo Equity
$25,000,000
IPO
Unknown
Series A
$48,000,000
Seed
$1,300,000
Series Unknown
$30,000,000
Series B
$10,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Alpine Immune Sciences.